{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:30:12Z","timestamp":1778113812530,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Poor COVID-19 outcomes occur with higher frequency in people with rheumatic and musculoskeletal diseases (RMD). Better understanding of the factors involved is crucial to informing patients and clinicians regarding risk mitigation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To describe COVID-19 outcomes for people with RMD in Ireland over the first 2\u00a0years of the pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data entered into the C19-GRA provider registry from Ireland between 24th March 2020 and 31<jats:sup>st<\/jats:sup> March 2022 were analysed. Differences in the likelihood of hospitalisation and mortality according to demographic and clinical variables were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 237 cases included, 59.9% were female, 95 (41.3%) were hospitalised, and 22 (9.3%) died. Hospitalisation was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular and pulmonary disease, and cancer. Hospitalisation was less frequent in people with inflammatory arthritis and conventional synthetic or biologic disease-modifying antirheumatic drug use. Hospitalisation had a <jats:italic>U<\/jats:italic>-shaped relationship with disease activity, being more common in both high disease activity and remission. Mortality was more common with increasing age, gout, smoking, long-term glucocorticoid use, comorbidities, and specific comorbidities of cardiovascular disease, pulmonary disease, and obesity. Inflammatory arthritis was less frequent in those who died.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hospitalisation or death were more frequently experienced by RMD patients with increasing age, certain comorbidities including potentially modifiable ones, and certain medications and diagnoses amongst other factors. These are important \u2018indicators\u2019 that can help risk-stratify and inform the management of RMD patients.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-022-03265-7","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T08:03:53Z","timestamp":1673251433000},"page":"2495-2500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2\u00a0years of the pandemic"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-3362","authenticated-orcid":false,"given":"Richard","family":"Conway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiana A.","family":"Demetriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Leamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael M.","family":"Flood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan H.","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean W.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine M.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the COVID-19 Global Rheumatology Alliance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"5","key":"3265_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/art.42030","volume":"74","author":"R Conway","year":"2022","unstructured":"Conway R, Grimshaw AA, Konig MF et al (2022) SARS-CoV-2 Infection and COVID-19 Outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol (Hoboken, NJ) 74(5):766\u2013775","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"5","key":"3265_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/M20-5327","volume":"174","author":"GL Anesi","year":"2021","unstructured":"Anesi GL, Jablonski J, Harhay MO et al (2021) Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med 174(5):613\u2013621","journal-title":"Ann Intern Med"},{"key":"3265_CR3","doi-asserted-by":"crossref","unstructured":"Roth GA, Emmons-Bell S, Alger HM et al (2021) Trends in patient characteristics and COVID-19 in-hospital mortality in the United States during the COVID-19 pandemic. JAMA Netw Open 4(5):e218828\u2013e","DOI":"10.1001\/jamanetworkopen.2021.8828"},{"key":"3265_CR4","unstructured":"Conway R, Nikiphorou E, Demetriou CA et al (2022) Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. Rheumatol (Oxford) 61(SI2):SI151\u2013SI6"},{"issue":"5","key":"3265_CR5","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","volume":"4","author":"L Wieske","year":"2022","unstructured":"Wieske L, van Dam KPJ, Steenhuis M et al (2022) Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol 4(5):e338\u2013e350","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"3265_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859\u2013866","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3265_CR7","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2665-9913(20)30095-3","volume":"2","author":"MA Gianfrancesco","year":"2020","unstructured":"Gianfrancesco MA, Hyrich KL, Gossec L et al (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2(5):e250\u2013e253","journal-title":"Lancet Rheumatol"},{"key":"3265_CR8","doi-asserted-by":"crossref","unstructured":"Conway R, Nikiphorou E, Demetriou CA et al (2021) Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. Rheumatol Adv Pract 5(2)","DOI":"10.1093\/rap\/rkab031"},{"issue":"7","key":"3265_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Schafer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942","journal-title":"Ann Rheum Dis"},{"key":"3265_CR10","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer M, Strangfeld A, Hyrich KL et al (2021)\u00a0 Response to: \u2018Correspondence on \u2018Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry\u2019\u2019 by Mulhearn et al. Ann Rheum Dis\u00a0annrheumdis-2021\u2013220134","DOI":"10.1136\/annrheumdis-2021-220134"},{"issue":"12","key":"3265_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","volume":"79","author":"JL Pablos","year":"2020","unstructured":"Pablos JL, Galindo M, Carmona L et al (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 79(12):1544\u20131549","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3265_CR12","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/S2665-9913(21)00316-7","volume":"3","author":"SE Sattui","year":"2021","unstructured":"Sattui SE, Conway R, Putman MS et al (2021) Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol 3(12):e855\u2013e864","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"3265_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM et al (2021) Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 80(9):1137\u20131146","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3265_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2021-220549","volume":"81","author":"R Felten","year":"2022","unstructured":"Felten R, Duret PM, Bauer E et al (2022) B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Ann Rheum Dis 81(1):143\u2013145","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3265_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29639","volume":"4","author":"Z Izadi","year":"2021","unstructured":"Izadi Z, Brenner EJ, Mahil SK et al (2021) Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 4(10):e2129639","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3265_CR16","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/S2665-9913(21)00008-4","volume":"3","author":"MA Gianfrancesco","year":"2021","unstructured":"Gianfrancesco MA, Robinson PC (2021) Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this? Lancet Rheumatol 3(2):e88\u2013e90","journal-title":"Lancet Rheumatol"},{"key":"3265_CR17","doi-asserted-by":"crossref","unstructured":"Flood RM, Conway R, Kirby C et al (2020) Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Ann Rheum Dis annrheumdis 218733","DOI":"10.1136\/annrheumdis-2020-218733"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03265-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:10:16Z","timestamp":1695777016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03265-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3265"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03265-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The views expressed here are those of the authors and do not necessarily represent the views of the American College of Rheumatology (ACR), the European Alliance of Associations for Rheumatology (EULAR), and the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR) or the (UK) Department of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Irish National Research Ethics Committee for COVID-19 (20-NREC-COV-010).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Richard Conway: speakers bureau Janssen, Roche, Sanofi, Abbvie, Clinical Trials: Abbvie, grant\/research support: Janssen; Elena Nikiphorou: speakers bureau: AbbVie, Eli-Lilly, Gilead, Celltrion, Pfizer, Sanofi, Fresenius, grant\/research support: Pfizer, Lilly; Christiana Demetriou: none declared; Candice Low: none declared; Kelly Leamy: none declared; John Ryan: none declared; Ronan Kavanagh: none declared; Alexander Fraser: none declared; John Carey: none declared; Paul O'Connell: none declared; Rachael Flood: none declared; Ronan Mullan: none declared; David Kane: none declared; Nicola Ambrose: none declared; Frances Stafford: none declared; Philip Robinson speakers bureau: UCB, Roche, Pfizer, Gilead, Janssen, Novartis; Eli Lilly, Abbvie, grant\/research support from: Abbvie, UCB, Novartis, Janssen, Pfizer; Jean Liew: grant\/research support from: Pfizer. Rebecca Grainger: speakers bureau: Pfizer, Cornerstones, Janssen, Novartis; Abbvie; Geraldine McCarthy: none declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}